… for patients with hepatitis B e antigen–positive CHB. A lower serum HBV DNA threshold
of 2000 IU/mL or more is recommended for patients with hepatitis B e antigen–negative CHB, …

Chronic HBV infection is an important public health problem worldwide and in the United
States. A treatment algorithm for the management of this disease, published previously by a …

The recent National Health and Nutrition Examination Survey (NHANES) sampled only the
civilian, non‐institutionalized population of USA and may have underestimated the …

OBJECTIVES: Needle liver biopsy has been shown to have a high rate of sampling error in
patients with diffuse parenchymal liver diseases. In these cases, the sample of liver tissue …

Background Only 15 to 20 percent of patients with chronic hepatitis C have a sustained
virologic response to interferon therapy. We compared the efficacy and safety of recombinant …

Background High rates of sustained virologic response were observed among patients with
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …

Background Treatment guidelines recommend the use of peginterferon alfa-2b or
peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. …

Background Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for
whom treatment with peginterferon is not an option, or who have not had a response to prior …

Background Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients
who have not had a sustained virologic response to prior interferon-based therapy represents …

… 23 percent, P<0.001), loss of hepatitis B e antigen (HBeAg) in serum (32 percent vs. 11
percent, P=0.003), sustained suppression of serum hepatitis B virus (HBV) DNA to undetectable …